skip to content

Clinical Trials

MainTitle

Study of Safety and Pharmacokinetics in Healthy Volunteers and Safety, Tolerability and Antiviral Activity of VM-1500 in Patients With Human Immunodeficiency Virus-1 Infection

This study has been completed
Sponsor
Viriom


Information provided by (Responsible Party)
Viriom
ClinicalTrials.gov Identifier
NCT02485509

First received: June 18, 2015
Last updated: June 25, 2015
Last Verified: June 2015
History of Changes
Purpose

Purpose

A combined Phase Ib and IIa randomized, placebo-controlled, double-blind study of VM-1500 in healthy subjects and in patients with HIV-1 infection that are antiretroviral therapy naïve.

Condition Intervention Phase
HIV Infection

Drug : VM-1500/Placebo
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Phase Ib/IIa, Single-Centre, Placebo-Controlled Randomized Study of Safety and Pharmacokinetics in Healthy Volunteers and Safety, Tolerability and Antiviral Activity of VM-1500 in Patients With Human Immunodeficiency Virus-1 Infection

Further study details as provided by Viriom:

Primary Outcome Measures

  • Safety and tolerability of VM-1500 in adult healthy subjects and in patients with early-stage chronic HIV-1 infection based on analysis of AEs, laboratory values. [ Time Frame: about one and half month ]
Secondary Outcome Measures:
  • Pharmacokinetic (PK) profile of VM-1500 in healthy subjects (Cmax, AUC, T1/2) and in HIV-1-infected patients. [ Time Frame: about one and half month ]
  • Dose dependency between VM-1500 plasma levels and corresponding HIV RNA reduction with the administered dosages of VM-1500. [ Time Frame: about one and half month ]
  • Virologic activity as measured by plasma HIV RNA following treatment for seven (7) days with VM-1500. [ Time Frame: about one and half month ]

Enrollment: 28
Study Start Date: March 2013
Study Completion Date: December 2013
Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)

Arms Assigned Interventions
Experimental: 20 mg VM-1500/Placebo Healthy group
VM-1500 20 mg or placebo single dose.
Drug: VM-1500/Placebo

VM-1500 or Placebo

Experimental: 40 mg VM-1500/Placebo Healthy group
VM-1500 40 mg or placebo single dose.
Drug: VM-1500/Placebo

VM-1500 or Placebo

Experimental: 20 mg VM-1500/Placebo Patient group
VM-1500 20 mg or placebo once daily for 7 days.
Drug: VM-1500/Placebo

VM-1500 or Placebo

Experimental: 40 mg VM-1500/Placebo Patient group
VM-1500 40 mg or placebo once daily for 7 days.
Drug: VM-1500/Placebo

VM-1500 or Placebo

Detailed Description:

The study will be split into two parts:
Part I: A randomized, placebo-controlled, single dose, double-blind study in healthy volunteers with 20 mg followed by 40 mg after DSMB approval.
Healthy group: one dose with 1 PK day 12 health volunteers (total): 6 subjects will randomized (4:2) to VM-1500 20 mg or placebo. After DSMB approval, 6 subjects will be randomized (4:2) to VM-1500 40 mg or placebo Part II: A randomized, placebo-controlled, multiple dose, double-blind study for 7 days in patients with HIV infection who are antiretroviral therapy-naïve. After positive DMSB review the dose will be escalated from 20 mg to 40 mg once daily.
Patient group: 2 PK days (in-house) at day 1 and day 7 16 patients (total): 8 subjects will be randomized (7:1) to VM-1500 20 mg or placebo once daily for 7 days. After DSMB approval, 8 subjects will be randomized (7:1) to VM-1500 40 mg or placebo once daily for 7 days.

Eligibility

Eligibility

Ages Eligible for Study: 18 Years to 65 Years  
Sexes Eligible for Study: All  
Accepts Healthy Volunteers: Yes  

Criteria

Inclusion Criteria for Healthy Subjects:

    1. Male age between 18-40 years
    2. Has been determined healthy by physical examination, assessment of drug abuse, medical history and vital signs
    3. Has normal results for the following screening tests: complete blood count , blood urea nitrogen, serum creatinine , fasting blood sugar, total bilirubin, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase and urinalysis.
    4. Negative result for hepatitis B, hepatitis C and HIV antibodies
    5. Willing to participate and signed the informed consent form

    Inclusion Criteria for Patients:
    1. Males or females aged 18 to 65 years
    2. HIV-1 infection, as documented by a rapid HIV test or any licensed ELISA test kit and confirmed by Western blot at any time prior to study entry
    3. Antiretroviral therapy naïve.

    Exclusion Criteria for Healthy Subjects:
    1. Hepatic or kidney disorders or any other disease or disorder which may in the opinion of the Investigator interfere with the results of the study or threaten the health of volunteers;
    2. Drug intake (including herbal drugs) during the last month;
    3. Active alcohol or and/or drug abuse that, in the opinion of the site investigator, would interfere with adherence to study requirements;
    4. Volunteers have taken any investigational drug at least 3 month prior to the start of the study;
    5. Inability to understand the Protocol or follow its instructions;

    Exclusion Criteria for Patients:
    1. Currently has any active AIDS defining illness
    2. Exclusionary resistance mutations defined as evidence of any major NNRTI mutations according to the current IAS list of HIV-1 Resistance Mutations Associated with Drug Resistance on any genotype; or evidence of significant NNRTI resistance on any phenotype performed at any time prior to study entry.
    3. Patients who are expected to need systemic antiviral therapy at any time during their participation in the study.
    4. Patients who have received an investigational drug for HIV, HIV vaccine, immunomodulators, systemic cytotoxic chemotherapy, or other investigational therapy within 30 days prior to study entry;
    5. Acute or chronic viral hepatitis;
    6. History or other evidence of renal disease.
    7. Abnormal hematological and biochemical parameters within 30 days of Entry (Day 1).
    8. Screening ECG QTc value 450 ms.
    9. Consumption / administration of concomitant medication.
    10. Active alcohol and/or drug abuse that, in the opinion of the site investigator, would interfere with adherence to study requirements.
    11. Positive results on urine screen for drugs of abuse at Screening or Day 1
    12. History of immunologically mediated disease.

contacts and locations

Contacts and Locations

Choosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02485509

Locations

Thailand
Faculty of Medicine, Siriraj Hospital
Bangkok, Wanglang Road, Thailand, 10700

Sponsors and Collaborators

Viriom
More Information

More Information


Responsible Party: Viriom  
ClinicalTrials.gov Identifier: NCT02485509   History of Changes  
Other Study ID Numbers: VM-1500-001  
Study First Received: June 18, 2015  
Last Updated: June 25, 2015  

Additional relevant MeSH terms:
Infection
Communicable Diseases
HIV Infections
Immunologic Deficiency Syndromes
Acquired Immunodeficiency Syndrome
Antiviral Agents

ClinicalTrials.gov processed this data on October 16, 2017
This information is provided by ClinicalTrials.gov.